Other PD-L1 and TGF-β dual-targeting agents, such as SHR-1701 and TQB2858, are currently under clinical evaluation, with early-phase studies indicating potential antitumor activity in NPC. This evidence concerns the gene TGFB1 and nasopharyngeal carcinoma.